MyMD Pharmaceuticals has secured USD 14 million in Series G and Series F-1 private placement rounds. The Series G round was led by strategic investor PharmaCyte, while the F-1 round saw participation from existing shareholders.

The company expects to use the funds for the clinical studies of MYMD-1 in sarcopenia (an age-related decline in physical function) for the next two years. MYMD-1 is an orally available, next-generation TNF-alpha inhibitor focused on TNF-alpha-based disease treatment.

MyMD is developing novel therapies for serious autoimmune and inflammatory diseases. The company claims that its lead candidate, MYMD-1, has the potential to be the first drug approved by the FDA for sarcopenia. The product is currently in Phase II studies for sarcopenia and frailty—conditions associated with aging—and early-stage trials for rheumatoid arthritis, with the potential for expansion into other applications.